Dimethyl-[2-(5-methyl-indol-1-yl)-ethyl]-amine | 87482-19-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: Dimethyl-[2-(5-methyl-indol-1-yl)-ethyl]-amine
• 英文别名: N,N-Dimethyl-2-(5-methyl-1H-indol-1-yl)ethan-1-amine；N,N-dimethyl-2-(5-methylindol-1-yl)ethanamine
• CAS: 87482-19-7
• 化学式: C₁₃H₁₈N₂
• 分子量: 202.299
• InChiKey: PQMAYIXYIYVYLM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  8.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  5-甲基吲哚 、 2-氯-N,N-二甲基乙胺 在 sodium hydride 作用下， 生成 Dimethyl-[2-(5-methyl-indol-1-yl)-ethyl]-amine
  参考文献：
  名称：

  Synthesis and evaluation of a novel series of N,N-dimethylisotryptamines

  摘要：

  A novel series of N,N-dimethylisotryptamine (isoDMT) derivatives, i.e., derivatives of 1-[2-(dimethylamino)ethyl]indole, was prepared and found to be isosteric with their corresponding N,N-dimethyltryptamine (DMT) counterparts with respect to serotonin receptor (rat fundus) affinity. Whereas the isoDMT derivatives possessed a greater affinity than did their corresponding DMT derivatives, they were relatively ineffective in displacing [3H]-5-HT binding from rat brain (cortex) homogenates. In a drug discrimination paradigm, using rats as subjects, 6-OMe-isoDMT produced effects similar to those of 5-OMe-DMT. Attempts to antagonize the discriminative stimulus effects of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) using two of the isoDMT derivatives proved unsuccessful.

  DOI：

  10.1021/jm00367a008

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE KINASE
  申请人：NUVATION BIO INC

  公开号：WO2021003314A1

  公开（公告）日：2021-01-07

  Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

  提供异环化合物作为CDK4或CDK6或其他CDK抑制剂。这些化合物可能作为治疗疾病的治疗剂，特别是在肿瘤学方面可能具有特殊用途。
• NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
  申请人：ACEA BIOSCIENCES INC.

  公开号：US20150210702A1

  公开（公告）日：2015-07-30

  The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways.

  本发明涉及某些吡咯吡嗪衍生物、包含它们的药物组合物以及使用它们的方法，包括用于治疗增殖障碍和与激酶调节失调相关的其他疾病的方法（例如，但不限于，EGFR（包括HER）、Alk、PDGFR、BLK、BMX/ETK、BTK、FLT3（D835Y）、ITK、JAK1、JAK2、JAK3、TEC和TXK）和/或相应途径的方法。
• QUINOLONE COMPOUND
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：EP3318557A2

  公开（公告）日：2018-05-09

  The present invention provides a compound represented by the formula (I) wherein X is a hydrogen atom or a fluorine atom; R is a hydrogen atom or alkyl; R1 is (1) cyclopropyl optionally substituted by 1 to 3 halogen atoms or (2) phenyl optionally substituted by 1 to 3 halogen atoms; R2 is alkyl, alkoxy, haloalkoxy, a halogen atom, cyano, etc.; and R3 is 7-oxo-7,8-dihydro-1,8-naphthyridinyl, 3-pyridyl, etc., or a salt thereof. The compound of the present invention has excellent antimicrobial activity against Clostridium difficile and is useful for the prevention or treatment of intestinal infection such as Clostridium difficile-associated diarrhea.

  本发明提供了一种由式 (I) 表示的化合物 其中 X 是氢原子或氟原子；R 是氢原子或烷基；R1 是(1)任选被 1 至 3 个卤素原子取代的环丙基或(2)任选被 1 至 3 个卤素原子取代的苯基；R2 是烷基、烷氧基、卤代烷氧基、卤素原子、氰基等；R3 是 7-氧代-7,8-二氢-1,8-萘啶基、3-吡啶基等或其盐。本发明的化合物对艰难梭菌具有优异的抗菌活性，可用于预防或治疗艰难梭菌相关性腹泻等肠道感染。
• Synthesis and evaluation of a novel series of N,N-dimethylisotryptamines
  作者：Richard A. Glennon、John M. Jacyno、R. Young、J. D. McKenney、David Nelson

  DOI：10.1021/jm00367a008

  日期：1984.1

  A novel series of N,N-dimethylisotryptamine (isoDMT) derivatives, i.e., derivatives of 1-[2-(dimethylamino)ethyl]indole, was prepared and found to be isosteric with their corresponding N,N-dimethyltryptamine (DMT) counterparts with respect to serotonin receptor (rat fundus) affinity. Whereas the isoDMT derivatives possessed a greater affinity than did their corresponding DMT derivatives, they were relatively ineffective in displacing [3H]-5-HT binding from rat brain (cortex) homogenates. In a drug discrimination paradigm, using rats as subjects, 6-OMe-isoDMT produced effects similar to those of 5-OMe-DMT. Attempts to antagonize the discriminative stimulus effects of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) using two of the isoDMT derivatives proved unsuccessful.